Bremelanotide
10mg / vial
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II. Unlike many compounds studied in this context, PT-141 acts centrally via the nervous system rather than the vascular system — making it a distinct and widely researched tool in melanocortin pathway studies.
PT-141 is a cyclic heptapeptide and metabolite of Melanotan II. It is an agonist at MC3R and MC4R — melanocortin receptors expressed in the brain and central nervous system. Its central mechanism distinguishes it from peripherally acting compounds studied in similar contexts.
By activating MC3R and MC4R in the hypothalamus, PT-141 engages pathways involved in CNS signalling independent of hormonal vascular mechanisms. Research has investigated its role in these receptor systems across neurological and behavioural models.
PT-141 has been extensively studied in melanocortin receptor research, CNS pathway modelling, and behavioural pharmacology. It was developed from Melanotan II and carries a well-documented research history spanning two decades.
Commonly researched with